AMGEN INC.Distribution Agreement • December 9th, 1997 • Amgen Inc • Biological products, (no disgnostic substances) • New York
EXHIBIT 7.11Purchase Agreement • March 22nd, 2001 • Amgen Inc • Biological products, (no disgnostic substances) • New York
AMGEN INC. ANDFirst Supplemental Indenture • March 14th, 1997 • Amgen Inc • Biological products, (no disgnostic substances) • New York
BY AND AMONG AMGEN INC.,Merger Agreement • December 17th, 2001 • Amgen Inc • Biological products, (no disgnostic substances) • Delaware
Amgen Inc. andRights Agreement • December 18th, 2000 • Amgen Inc • Biological products, (no disgnostic substances) • Delaware
AGREEMENT ---------Rights Agreement • February 28th, 1997 • Amgen Inc • Biological products, (no disgnostic substances) • Delaware
EXHIBIT 99.7 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this "Agreement"), made and entered into as of the Effective Date (as hereinafter defined), between Amgen Inc., a Delaware corporation (the "Company"), and Edward V. Fritzky (the...Employment Agreement • January 31st, 2002 • Amgen Inc • Biological products, (no disgnostic substances) • Washington
between AMGEN INC. andRegistration Rights Agreement • November 19th, 2004 • Amgen Inc • Biological products, (no disgnostic substances) • New York
AMGEN INC.Purchase Agreement • November 19th, 2004 • Amgen Inc • Biological products, (no disgnostic substances) • New York
EXHIBIT 7.3 =================================================================== ============= REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • October 28th, 1997 • Amgen Inc • Biological products, (no disgnostic substances) • Delaware
EXHIBIT 1.1 UNDERWRITING AGREEMENTUnderwriting Agreement • December 5th, 1997 • Amgen Inc • Biological products, (no disgnostic substances) • New York
FIRST AMENDMENT TO CREDIT AGREEMENTCredit Agreement • March 24th, 1997 • Amgen Inc • Biological products, (no disgnostic substances) • California
OFShareholders' Agreement • March 7th, 2001 • Amgen Inc • Biological products, (no disgnostic substances) • California
EXHIBIT 8.1 [LETTERHEAD OF LATHAM & WATKINS] July 15, 2002 Amgen Inc. One Amgen Center Drive Thousand Oaks, California 91320 Re: Amended and Restated Agreement and Plan of Merger by and among Amgen Inc., AMS Acquisition Inc. and Immunex Corporation...Agreement and Plan of Merger • July 15th, 2002 • Amgen Inc • Biological products, (no disgnostic substances)
Page ARTICLE 1 DEFINITIONS AND ACCOUNTING TERMS................ 1 -------------------------------- 1.1 Defined Terms.............................................. 1 ------------- 1.2 Use of Defined Terms....................................... 18...Credit Agreement • August 14th, 1998 • Amgen Inc • Biological products, (no disgnostic substances) • California
Amgen Inc. andRights Agreement • February 28th, 1997 • Amgen Inc • Biological products, (no disgnostic substances) • Delaware
ARTICLE 1 DEFINITIONS AND ACCOUNTING TERMSCredit Agreement • August 6th, 2004 • Amgen Inc • Biological products, (no disgnostic substances) • New York
AMENDMENT NO. 1 TO WARRANT AGREEMENTWarrant Agreement • March 7th, 2000 • Amgen Inc • Biological products, (no disgnostic substances) • New York
Exhibit 10.68 RESTRICTED STOCK PURCHASE AGREEMENT JOSEPH P. MILETICH, Amgen Inc. Grantee: On this 1st day of April, 2002, Amgen Inc., a Delaware corporation (the "Company"), pursuant to its Amended and Restated 1991 Equity Incentive Plan (the "Plan")...Restricted Stock Purchase Agreement • April 29th, 2002 • Amgen Inc • Biological products, (no disgnostic substances)
AMGEN INC. $1,000,000,000 3.200% SENIOR NOTES DUE 2027 Underwriting AgreementUnderwriting Agreement • November 2nd, 2017 • Amgen Inc • Biological products, (no disgnostic substances) • New York
Amgen Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of $1,000,000,000 principal amount of its 3.200% Senior Notes due 2027 (the “Securities”) to be issued pursuant to the provisions of an Indenture dated as of May 22, 2014 (the “Indenture”), between the Company and The Bank of New York Mellon Trust Company, N.A., as Trustee (the “Trustee”). J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC and BNP Paribas Securities Corp. have agreed to act as representatives of the Underwriters (the “Representatives”).
Annex D RESTRICTED STOCK UNIT AGREEMENT _____________________, Amgen Inc. Grantee: On this __ day of _______________ (the "Grant Date"), Amgen Inc., a Delaware corporation (the "Company"), pursuant to its Director Equity Incentive Program (the...Restricted Stock Unit Agreement • March 11th, 2004 • Amgen Inc • Biological products, (no disgnostic substances) • Delaware
This AGREEMENT REGARDING GOVERNANCE AND COMMERCIAL MATTERS (this "Agreement"), dated December 16, 2001, is entered into by and among American --------- Home Products Corporation, a Delaware corporation ("AHP"), American Cyanamid --- Company, a Maine...Governance Agreement • March 22nd, 2002 • Amgen Inc • Biological products, (no disgnostic substances) • Delaware
WHEREAS, as of the date hereof, each Shareholder "beneficially owns" (as such term is defined in Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) and is entitled to dispose of (or to direct the disposition of) and to vote...Shareholder Voting Agreement • December 17th, 2001 • Amgen Inc • Biological products, (no disgnostic substances) • Delaware
AGREEMENT AND PLAN OF MERGER by and among: ONYX PHARMACEUTICALS, INC., a Delaware corporation; AMGEN INC., a Delaware corporation; and ARENA ACQUISITION COMPANY, a Delaware corporation Dated as of August 24, 2013Merger Agreement • August 26th, 2013 • Amgen Inc • Biological products, (no disgnostic substances) • New York
Registration Rights Agreement Dated As of February 17, 2006 between Amgen Inc. and Merrill Lynch, Pierce, Fenner & Smith Incorporated and Morgan Stanley & Co. IncorporatedRegistration Rights Agreement • February 21st, 2006 • Amgen Inc • Biological products, (no disgnostic substances) • New York
This Registration Rights Agreement (the “Agreement”) is made and entered into this 17th day of February, 2006, among Amgen Inc., a Delaware corporation (the “Company”) and Merrill Lynch, Pierce, Fenner & Smith Incorporated (“Merrill Lynch”) and Morgan Stanley & Co. Incorporated (“Morgan Stanley”), acting on behalf of the several parties named in Schedule A to the Purchase Agreement (as defined below) (collectively, the “Initial Purchasers”).
Annex B PERFORMANCE UNIT AGREEMENT __________________, Amgen Inc. Grantee: On this __ day of _______________ (the "Grant Date"), Amgen Inc., a Delaware corporation (the "Company"), pursuant to its Performance Award Program (the "Program") which...Performance Unit Agreement • March 11th, 2004 • Amgen Inc • Biological products, (no disgnostic substances) • Delaware
AMGEN INC. $1,250,000,000 2.125% SENIOR NOTES DUE 2017 $750,000,000 3.625% SENIOR NOTES DUE 2022 $1,000,000,000 5.375% SENIOR NOTES DUE 2043 Underwriting AgreementUnderwriting Agreement • May 15th, 2012 • Amgen Inc • Biological products, (no disgnostic substances) • New York
Amgen Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of $1,250,000,000 principal amount of the 2.125% Senior Notes due 2017 of the Company (the “2017 Notes”), an aggregate of $750,000,000 principal amount of the 3.625% Senior Notes due 2022 of the Company (the “2022 Notes”) and an aggregate of $1,000,000,000 principal amount of the 5.375% Senior Notes due 2043 of the Company (the “2043 Notes”, and together with the 2017 Notes and the 2022 Notes, collectively,
BY AND BETWEEN AMGEN,Assignment and License Agreement • March 7th, 2001 • Amgen Inc • Biological products, (no disgnostic substances) • California
WITNESSETH: ----------Product License Agreement • August 1st, 2000 • Amgen Inc • Biological products, (no disgnostic substances) • California
Form of Award NoticeAward Notice • February 13th, 2019 • Amgen Inc • Biological products, (no disgnostic substances) • Delaware
This notice of Award (the “Award Notice”) sets forth certain details relating to the grant by the Company to you of the Award identified below, pursuant to the Plan. The terms of this Award Notice are incorporated into the Agreement that accompanies this Award Notice and made part of the Agreement. Capitalized terms used in this Award Notice that are not otherwise defined in this Award Notice have the meanings given to such terms in the Agreement.
Form of Award NoticeAward Notice • May 3rd, 2013 • Amgen Inc • Biological products, (no disgnostic substances)
This notice of Award (the “Award Notice”) sets forth certain details relating to the grant by the Company to you of the Award identified below, pursuant to the Plan. The terms of this Award Notice are incorporated into the Agreement that accompanies this Award Notice and made part of the Agreement. Capitalized terms used in this Award Notice that are not otherwise defined in this Award Notice have the meanings given to such terms in the Agreement.
March 2, 2000Stock Purchase Agreement • March 7th, 2000 • Amgen Inc • Biological products, (no disgnostic substances)
Form of Award NoticeAward Notice • February 13th, 2019 • Amgen Inc • Biological products, (no disgnostic substances) • Delaware
This notice of Award (the “Award Notice”) sets forth certain details relating to the grant by the Company to you of the Award identified below, pursuant to the Plan. The terms of this Award Notice are incorporated into the Agreement that accompanies this Award Notice and made part of the Agreement. Capitalized terms used in this Award Notice that are not otherwise defined in this Award Notice have the meanings given to such terms in the Agreement.
AGREEMENT AND PLAN OF MERGER Among Abgenix, Inc., Amgen Inc. and Athletics Merger Sub, Inc. Dated as of December 14, 2005Merger Agreement • December 15th, 2005 • Amgen Inc • Biological products, (no disgnostic substances) • Delaware
AGREEMENT AND PLAN OF MERGER (hereinafter called this “Agreement”), dated as of December 14, 2005, among Abgenix, Inc., a Delaware corporation (the “Company”), Amgen Inc., a Delaware corporation (“Parent”), and Athletics Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (“Merger Sub,” the Company and Merger Sub sometimes being hereinafter collectively referred to as the “Constituent Corporations”).
EXHIBIT 7.9 March 12, 2001 MERRILL LYNCH & CO. Merrill Lynch, Pierce, Fenner & Smith Incorporated J.P. MORGAN SECURITIES INC. ROBERTSON STEPHENS, INC. as Representative(s) of the several Underwriters to be named in the within- mentioned Purchase...Public Offering Agreement • March 13th, 2001 • Amgen Inc • Biological products, (no disgnostic substances)
MERRILL LYNCH & CO. Merrill Lynch, Pierce, Fenner & Smith Incorporated J.P. MORGAN SECURITIES INC. ROBERTSON STEPHENS, INC. as Representative(s) of the several Underwriters to be named in the within-mentioned Purchase Agreement c/o Merrill Lynch & Co. Merrill Lynch, Pierce, Fenner & Smith Incorporated North Tower World Financial Center New York, New York 10281
